ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptimmune Therapeutics PLC
Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026
- Market cap
- $55.46M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.0%
0M of 1.59B shares
Institutional holders
0
0 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Two Seas Capital LP | 89,010,876 | 5.80% | 13G (passive) | Dec 31, 2024 |
| Sina Toussi | 135,484,206 | 8.50% | 13G (passive) amendment | Jun 30, 2025 |
| Matrix Capital Management Company LP | 135,000,000 | 8.80% | 13G (passive) amendment | Nov 30, 2024 |
Top institutional holders
13F holdings as of Mar 31, 2026
| Holder | Shares | % of ADAPY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rhumbline Advisers | 3,661 | 0.00% | $72 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 1 | 0M | 0.0% | 0 / 0 | 0 / 9 | 0M | 2M |
| Q4 2025 | 10 | 2M | 0.1% | 1 / 3 | 4 / 46 | 1M | 41M |
| Q3 2025 | 55 | 42M | 2.6% | 14 / 7 | 12 / 24 | 13M | 86M |
| Q2 2025 | 65 | 116M | 7.3% | 11 / 10 | 18 / 11 | 5M | 5M |
| Q1 2025 | 67 | 116M | 7.3% | 8 / 17 | 16 / 19 | 14M | 22M |
| Q4 2024 | 80 | 124M | 7.8% | 14 / 19 | 21 / 14 | 25M | 53M |
| Q3 2024 | 81 | 153M | 9.6% | 18 / 21 | 15 / 12 | 5M | 7M |
| Q2 2024 | 76 | 155M | 9.7% | 7 / 16 | 22 / 11 | 3M | 12M |
| Q1 2024 | 80 | 164M | 10.3% | 16 / 17 | 23 / 15 | 30M | 13M |
| Q4 2023 | 79 | 146M | 9.2% | 14 / 16 | 25 / 14 | 5M | 7M |
| Q3 2023 | 79 | 148M | 9.3% | 7 / 16 | 24 / 17 | 7M | 3M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adrian Rawcliffe | Chief Executive Officer, Director | 44,327 | 0.00% | Feb 20, 2025 |
| Christopher James Hill | Chief Financial Officer | – | – | Oct 8, 2025 |
| Gavin Wood | Chief Financial Officer | 0 | – | Sep 3, 2025 |
| William C. Bertrand JR | Chief Operating Officer | 986,352 | 0.06% | Aug 29, 2025 |
| John Lunger | Chief Patient Supply Officer | 7,510 | 0.00% | Feb 20, 2025 |
| Cintia Piccina | Chief Commercial Officer | 18,421 | 0.00% | Feb 20, 2025 |
| Elliot Norry | Chief Medical Officer | 7,510 | 0.00% | Feb 20, 2025 |
| Joanna Elizabeth Brewer | Chief Scientific Officer | – | – | Feb 20, 2025 |
| Ali Behbahani | Director | 0 | – | Aug 19, 2025 |
| EcoR1 Capital, LLC | 10% owner | 100,371,882 | 6.31% | Jul 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gavin Wood Chief Financial Officer | Sep 2, 2025 | Sale | −96,000 | $0.01 | $960 | 0 |
| William C. Bertrand JR Chief Operating Officer | Aug 28, 2025 | Sale | −207,000 | $0.01 | $2.07K | 986,352 |
| Ali Behbahani Director | Aug 18, 2025 | Sale | −14,671,794 | $0.01 | $146.72K | 0 |
| Ali Behbahani Director | Aug 15, 2025 | Sale | −4,828,206 | $0.01 | $48.28K | 14,671,794 |
| EcoR1 Capital, LLC 10% owner | Jul 30, 2025 | Sale | −27,433,338 | $0.10 | $2.74M | 100,371,882 |
| EcoR1 Capital, LLC 10% owner | Jul 29, 2025 | Sale | −2,687,460 | $0.10 | $268.75K | 127,805,220 |
| EcoR1 Capital, LLC 10% owner | Jul 28, 2025 | Sale | −33,931,740 | $0.11 | $3.73M | 130,492,680 |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2025 | Sale | −5,584 | $0.58 | $3.24K | 7,510 |
| Elliot Norry Chief Medical Officer | Jan 17, 2025 | Sale | −5,584 | $0.58 | $3.24K | 7,510 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 17, 2025 | Sale | −30,601 | $0.58 | $17.75K | 44,327 |
| John Lunger Chief Patient Supply Officer | Jan 17, 2025 | Sale | −5,584 | $0.58 | $3.24K | 7,510 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 15, 2025 | Sale | −29,096 | $0.57 | $16.58K | 41,582 |
| William C. Bertrand JR Chief Operating Officer | Jan 15, 2025 | Sale | −9,803 | $0.57 | $5.59K | 13,756 |
| Cintia Piccina Chief Commercial Officer | Jan 15, 2025 | Sale | −12,991 | $0.57 | $7.40K | 18,421 |
| Elliot Norry Chief Medical Officer | Jan 15, 2025 | Sale | −9,803 | $0.57 | $5.59K | 13,756 |
| John Lunger Chief Patient Supply Officer | Jan 15, 2025 | Sale | −9,803 | $0.57 | $5.59K | 13,756 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 13, 2025 | Sale | −17,934 | $0.59 | $10.58K | 25,711 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 13, 2025 | Sale | −12,539 | $0.59 | $7.40K | 17,801 |
| William C. Bertrand JR Chief Operating Officer | Jan 13, 2025 | Sale | −4,268 | $0.59 | $2.52K | 5,845 |
| William C. Bertrand JR Chief Operating Officer | Jan 13, 2025 | Sale | −5,471 | $0.59 | $3.23K | 7,623 |
| Elliot Norry Chief Medical Officer | Jan 13, 2025 | Sale | −8,124 | $0.59 | $4.79K | 11,516 |
| Elliot Norry Chief Medical Officer | Jan 13, 2025 | Sale | −4,268 | $0.59 | $2.52K | 5,845 |
| John Lunger Chief Patient Supply Officer | Jan 13, 2025 | Sale | −4,268 | $0.59 | $2.52K | 5,845 |
| John Lunger Chief Patient Supply Officer | Jan 13, 2025 | Sale | −5,471 | $0.59 | $3.23K | 7,623 |
| Cintia Piccina Chief Commercial Officer | Jun 18, 2024 | Sale | −24,531 | $0.93 | $22.81K | 38,293 |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2024 | Sale | −5,309 | $0.67 | $3.56K | 7,785 |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2024 | Sale | −13,599 | $0.67 | $9.11K | 20,201 |
| John Lunger Chief Patient Supply Officer | Jan 17, 2024 | Sale | −12,805 | $0.67 | $8.58K | 19,015 |
| John Lunger Chief Patient Supply Officer | Jan 17, 2024 | Sale | −5,309 | $0.67 | $3.56K | 7,785 |
| Elliot Norry Chief Medical Officer | Jan 17, 2024 | Sale | −12,967 | $0.67 | $8.69K | 19,257 |
| Elliot Norry Chief Medical Officer | Jan 17, 2024 | Sale | −5,309 | $0.67 | $3.56K | 7,785 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 17, 2024 | Sale | −30,080 | $0.67 | $20.15K | 44,848 |
| William C. Bertrand JR Chief Operating Officer | Jan 16, 2024 | Sale | −4,681 | $0.79 | $3.70K | 7,023 |
| John Lunger Chief Patient Supply Officer | Jan 16, 2024 | Sale | −4,681 | $0.79 | $3.70K | 7,023 |
| Elliot Norry Chief Medical Officer | Jan 16, 2024 | Sale | −2,287 | $0.79 | $1.81K | 3,363 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 16, 2024 | Sale | −9,304 | $0.79 | $7.35K | 14,104 |
| John Lunger Chief Patient Supply Officer | Jan 12, 2024 | Sale | −5,220 | $0.85 | $4.44K | 7,874 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 12, 2024 | Sale | −17,257 | $0.85 | $14.67K | 26,388 |
| Elliot Norry Chief Medical Officer | Jan 12, 2024 | Sale | −7,799 | $0.85 | $6.63K | 11,841 |
| William C. Bertrand JR Chief Operating Officer | Jan 12, 2024 | Sale | −5,220 | $0.85 | $4.44K | 7,874 |
| John Lunger Chief Patient Supply Officer | Jan 11, 2024 | Sale | −4,009 | $0.84 | $3.37K | 6,104 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 11, 2024 | Sale | −11,945 | $0.84 | $10.03K | 18,395 |
| Elliot Norry Chief Medical Officer | Jan 11, 2024 | Sale | −4,009 | $0.84 | $3.37K | 6,104 |
| William C. Bertrand JR Chief Operating Officer | Jan 11, 2024 | Sale | −4,009 | $0.84 | $3.37K | 6,104 |
| Adrian Rawcliffe Chief Executive Officer, Director | Sep 1, 2023 | Sale | −2,403 | $0.78 | $1.87K | 3,449 |
| John Lunger Chief Patient Supply Officer | Aug 1, 2023 | Sale | −3,096 | $0.91 | $2.82K | 4,718 |
| Garry E. Menzel Director | Jul 10, 2023 | Sale | −47,702 | $0.91 | $43.41K | 75,056 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jun 27, 2023 | Sale | −2,333 | $0.92 | $2.15K | 3,519 |
| Garry E. Menzel Director | Jun 1, 2023 | Award | +200,646 | – | – | 200,646 |
| Garry E. Menzel Director | Jun 1, 2023 | Award | +200,647 | – | – | 200,647 |
| Garry E. Menzel Director | Jun 1, 2023 | Award | +209,931 | – | – | 209,931 |
| Cintia Piccina Chief Commercial Officer | Jan 31, 2023 | Sale | −11,890 | $1.87 | $22.23K | 19,535 |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2023 | Sale | −4,440 | $1.86 | $8.26K | 7,264 |
| Elliot Norry Chief Medical Officer | Jan 17, 2023 | Sale | −2,159 | $1.86 | $4.02K | 3,491 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 17, 2023 | Sale | −10,057 | $1.86 | $18.71K | 13,351 |
| John Lunger Chief Patient Supply Officer | Jan 17, 2023 | Sale | −4,440 | $1.86 | $8.26K | 7,264 |
| William C. Bertrand JR Chief Operating Officer | Jan 12, 2023 | Sale | −4,973 | $1.71 | $8.50K | 8,121 |
| Adrian Rawcliffe Chief Executive Officer, Director | Jan 12, 2023 | Sale | −18,763 | $1.71 | $32.08K | 24,882 |
| Elliot Norry Chief Medical Officer | Jan 12, 2023 | Sale | −7,449 | $1.71 | $12.74K | 12,191 |
| John Lunger Chief Patient Supply Officer | Jan 12, 2023 | Sale | −4,973 | $1.71 | $8.50K | 8,121 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Wood Gavin Chief Financial Officer | Sep 2, 2025 | 16,000 | $942 | Sep 2, 2025 | Open market purchase |
| Bertrand William Chief Operating Officer | Aug 29, 2025 | 34,500 | $2.07K | Aug 28, 2025 | Open market purchase |
| New Enterprise Associates, 14 LP Affiliate | Aug 15, 2025 | 13,829,778 | $981.91K | Aug 15, 2025 | Private Placement |
| New Enterprise Associates, 16 LP Affiliate | Aug 15, 2025 | 3,250,000 | $230.75K | Aug 15, 2025 | Private Placement |
| Elliot Norry Chief Medical Officer | Jan 17, 2025 | 5,584 | $3.24K | Jan 17, 2025 | Sell to cover exercise (cashless) |
| Adrian Rawcliffe Chief Executive Officer | Jan 17, 2025 | 30,601 | $17.77K | Jan 17, 2025 | Sell to cover exercise (cashless) |
| John Lunger Chief Patient Supply Officer | Jan 17, 2025 | 5,584 | $3.24K | Jan 17, 2025 | Sell to cover exercise (cashless) |
| William C. Bertrand JR Chief Operating Officer | Jan 17, 2025 | 5,584 | $3.24K | Jan 17, 2025 | Sell to cover exercise (cashless) |
| Elliot Norry Chief Medical Officer | Jan 15, 2025 | 22,195 | $12.92K | Jan 13, 2025 | Sell to cover exercise (cashless) |
| Adrian Rawcliffe Chief Executive Officer | Jan 15, 2025 | 59,569 | $34.64K | Jan 13, 2025 | Sell to cover exercise (cashless) |
| Cintia Piccina Chief Commercial Officer | Jan 15, 2025 | 12,991 | $7.47K | Jan 15, 2025 | Sell to cover exercise (cashless) |
| William C. Bertrand JR Chief Operating Officer | Jan 15, 2025 | 19,542 | $11.36K | Jan 13, 2025 | Sell to cover exercise (cashless) |
| John Lunger Chief Patient Supply Officer | Jan 15, 2025 | 19,542 | $11.36K | Jan 13, 2025 | Sell to cover exercise (cashless) |